Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma.

CONCLUSIONS: Anlotinib showed antitumor activity in several STS entities. The toxicity was manageable.
PMID: 29895706 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - June 12, 2018 Category: Cancer & Oncology Authors: Chi Y, Fang Z, Hong XN, Yao Y, Sun P, Wang G, Du F, Sun Y, Wu Q, Qu G, Wang S, Song J, Yu J, Lu Y, Zhu X, Niu X, He Z, Wang J, Yu H, Cai J Tags: Clin Cancer Res Source Type: research